Latest Breaking News On - Juan carlos jaramillo - Page 8 : comparemela.com

Valneva Reports Positive Safety Data In Adolescents For Chikungunya Vaccine Candidate

Valneva SE (VALN) reported positive initial Phase 3 safety data in adolescents for its single-dose chikungunya virus vaccine candidate VLA1553. The company said the initial safety data generated in the trial VLA1553-321 showed that VLA1553 was generally safe and well tolerated in adolescents aged 12 to 17 years, regardless of previous CHIKV infection.

Juan carlos jaramilloMore such health newsEuropean medicines agencyCarlos jaramilloChief medical officerChikungunya vaccine

VALNEVA: Valneva Reports Positive Initial Phase 3 Safety Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate

VALNEVA: Valneva Reports Positive Initial Phase 3 Safety Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesJuan carlos jaramilloJoshua drummInstituto butantanCoalition for epidemic preparedness innovationsDrug administrationEuropean union horizonHealth canadaEuropean medicines agencyVp global communications european investor relationsEuronext parisEpidemic preparedness innovationsChief medical officerBiologic license applicationPrescription drug user fee actSoutheast asia

Valneva Reports Positive Initial Phase 3 Safety Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate

Saint-Herblain (France), August 28, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive initial Phase 3 safety data in adolescents for its single-dose chikungunya virus (CHIKV) vaccine candidate VLA1553. Immunogenicity data for the trial are expected in November 2023. Funded by the Coalition for Epidemic Preparedness Innovations (CEPI) and conducted in collaboration with Instituto Butantan, the VLA1553-321 adolescent trial is intended to su

United statesJuan carlos jaramilloJoshua drummInstituto butantanDrug administrationVp global communications european investor relationsHealth canadaCoalition for epidemic preparedness innovationsEuropean union horizonEuropean medicines agencyEuronext parisEpidemic preparedness innovationsChief medical officerBiologic license applicationPrescription drug user fee actSoutheast asia

Valneva Reports Positive Initial Phase 3 Safety Data In Adolescents For Its Single-Shot Chikungunya Vaccine Candidate

Valneva Reports Positive Initial Phase 3 Safety Data In Adolescents For Its Single-Shot Chikungunya Vaccine Candidate
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesInstituto butantanJuan carlos jaramilloCoalition for epidemic preparedness innovationsEuropean medicines agencyDrug administrationEuropean union horizonHealth canadaEuronext parisEpidemic preparedness innovationsChief medical officerBiologic license applicationPrescription drug user fee actSoutheast asiaMiddle income countriesEuropean union

FDA extends approval deadline for Valneva s chikungunya vaccine by 3 months

FDA extends approval deadline for Valneva s chikungunya vaccine by 3 months
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

United statesJuan carlos jaramilloPrescription drug user fee actCarlos jaramillo